‘Cold’ Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14,... The post ‘Cold’ Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies appeared first on Montreal Gazette .

Original source: Montreal Gazette